Skip to content
Clinical Trials – home
Medical Center - University Of Freiburg
Sponsor

Medical Center - University Of Freiburg

Germany Breisacher Strasse 153, Mooswald, 79110 Freiburg Im Breisgau, Germany

About the sponsor

Clinical research includes aneurysmal subarachnoid hemorrhage, with interest in interventions aimed at improving neurological outcome and preventing secondary brain injury.

  • Subarachnoid hemorrhage
  • Intracranial vascular injury
  • Neuroprotection

The sponsor’s work in this area centers on acute brain injury and recovery after hemorrhagic events.

About Specializations

Medical Center - University Of Freiburg runs clinical trials in conditions such as Chronic graft versus host disease, Diffuse large B-cell lymphoma, Subarachnoid haemorrhage, Cytomegalovirus infection, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

12 clinical trials

A Study of Belumosudil for Patients with Steroid-Resistant Overlap Syndrome Graft-versus-Host Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belumosudil Mesilate
  • Sponsor:Medical Center - University Of Freiburg

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Busulfan
  • Sponsor:Medical Center - University Of Freiburg

Study on Ruxolitinib and Methoxsalen for Patients with Steroid-Refractory Chronic Graft-versus-Host Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Methoxsalen
  • Sponsor:Medical Center - University Of Freiburg

Study on Stereotactic Cisternal Lavage Therapy for Patients with Aneurysmal Subarachnoid Hemorrhage Using Urokinase, Nimodipine, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nimodipine
  • Sponsor:Medical Center - University Of Freiburg

Study on Treating Resistant Viral Infections in Stem Cell Transplant Patients Using Allogeneic Multivirus-Specific T Cells

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Allogeneic Cd4+ And Cd8+ T Lymphocytes Ex Vivo Incubated With Synthetic Peptides Of The Viral Antigens Of Cytomegalovirus, Adenovirus And Epstein-Barr Virus
  • Sponsor:Medical Center - University Of Freiburg

Study on Decitabine, Venetoclax, and Tretinoin for Patients with Acute Myeloid Leukemia Who Cannot Have Induction Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Medical Center - University Of Freiburg

Phase 2 study of lutetium (177Lu) vipivotide tetraxetan with ADT and darolutamide in patients with metastatic hormone‑sensitive prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:Medical Center - University Of Freiburg

Cartilage injury

Not yet recruiting

Non‑inferiority study of autologous minced cartilage and autologous cultured chondrocytes in adults with large full‑thickness knee cartilage defects

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Medical Center - University Of Freiburg

Adverse drug reaction+1

Not recruiting

Study on Methoxsalen for Treating Immune-Related Side Effects in Patients After Immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Methoxsalen
  • Sponsor:Medical Center - University Of Freiburg

Study of Pembrolizumab with Radiotherapy for Patients with Recurrent Prostate Cancer After Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Medical Center - University Of Freiburg

Metastatic neoplasm+1

Not recruiting

Study on Treating Advanced Cancers with BRAF Mutations Using Sorafenib and Trametinib for Patients with Impaired Kinase Activity

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sorafenib
  • Sponsor:Medical Center - University Of Freiburg

Myopia

Not recruiting

Study on Low-Dose Atropine Sulfate Eye Drops for Controlling Progressive Myopia in Caucasian Children

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Atropine Sulfate
  • Sponsor:Medical Center - University Of Freiburg

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.